Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAmeriHealth VIP Care Botulinum Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentAmeriHealth Caritas VIP CarePolicy CCP.1464

    Botulinum Toxin for Constipation

    Customize your policy alerts

    Sign up for amerihealth_caritas_vip_care Policy CCP.1464 alerts

    Get alerted when Policy CCP.1464 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of intrasphincteric botulinum toxin injection for refractory constipation and related defecatory disorders, identifying specific clinically proven indications and excluding other chronic defecatory disorders as investigational and not medically necessary.

    Policy Summary
    PayerAmeriHealth Caritas VIP Care
    PolicyBotulinum Toxin for Constipation
    Policy CodePolicy CCP.1464
    Change TypeCoverage criteria updated
    Effective DateAugust 1, 2020
    Last ReviewJul 1, 2026
    Next Review DateOctober 1, 2027
    Key ActionUse coverage criteria only for Hirschsprung disease after pull-through surgery, internal anal sphincter achalasia before myectomy is considered, or dyssynergic defecation.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage was modified in 2025 to add dyssynergic defecation as a covered indication based on a new professional guideline recommendation.

    The 2026 review updated references, reorganized the findings, and added a NASPGHAN guideline without changing policy coverage.

    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered clinical indications
    60-100 unitsPostoperative Hirschsprung dose
    3-6 monthsRepeat injection interval
    15%Chronic constipation prevalence
    Not coveredOther chronic defecatory disorders

    Medical Necessity and Coverage Criteria

    Medically necessary indications

    Intrasphincteric botulinum toxin injection for refractory constipation may be medically necessary when any one of the following indications is present.

    Covered indications

    • Postoperative Hirschsprung disease: The patient has Hirschsprung disease after corrective pull-through surgery.
    • Internal anal sphincter achalasia: The patient has internal anal sphincter achalasia and injection is performed before posterior internal anal sphincter myectomy is considered.
    • Dyssynergic defecation: The patient has dyssynergic defecation.

    Botulinum toxin injection for chronic defecatory disorders outside the policy-listed indications is considered investigational and not clinically proven.

    Injection for other chronic defecatory disorders is not medically necessary.

    Related Codes

    Related codesmixed
    46505Chemodenervation of internal anal sphincter
    J0585Injection, onabotulinumtoxinA, 1 unit
    J0586Injection, abobotulinumtoxinA, 5 units
    J0588Injection, incobotulinumtoxinA, 1 unit

    Provider Guidance and Coverage Limitations

    Denial Risk

    Avoid injection for non-covered disorders

    Do not use botulinum toxin injection for chronic defecatory disorders other than the policy-listed indications. Such injection is investigational/not clinically proven and, therefore, not medically necessary.

    Clinical Background

    Chronic constipation affects approximately 15% of the general population. Initial management commonly includes stool softeners, fiber, osmotic or stimulant laxatives, and secretagogues such as lubiprostone or linaclotide. The policy addresses selected refractory defecatory disorders for which intrasphincteric botulinum toxin may temporarily relax the internal anal sphincter or other targeted muscles.

    Clinical Definitions

    Hirschsprung disease
    ConditionA congenital disorder affecting a segment of the bowel.
    Ganglion cellsGanglion cells (nerve cells) are absent in the affected bowel segment, causing ineffective peristalsis and potentially severe constipation or bowel obstruction.
    Rectoanal inhibitory reflexThe rectoanal inhibitory reflex is absent on rectoanal manometry.
    Internal anal sphincter achalasia
    Manometry findingThe rectoanal inhibitory reflex is absent on manometry.
    Rectal suction biopsyGanglion cells are present on rectal suction biopsy, unlike in Hirschsprung disease.
    Policy Summary
    PayerAmeriHealth Caritas VIP Care
    PolicyBotulinum Toxin for Constipation
    Policy CodePolicy CCP.1464
    Change TypeCoverage criteria updated
    Effective DateAugust 1, 2020
    Last ReviewJul 1, 2026
    Next Review DateOctober 1, 2027
    Key ActionUse coverage criteria only for Hirschsprung disease after pull-through surgery, internal anal sphincter achalasia before myectomy is considered, or dyssynergic defecation.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaRelated CodesProvider Guidance and Coverage LimitationsClinical BackgroundClinical Definitions
    Clinical condition
    Internal anal sphincter achalasia is a clinical condition associated with the absent reflex despite the presence of ganglion cells.
    Dyssynergic defecation
    Disorder typeAn outlet dysfunction disorder that is a common cause of constipation.
    Puborectalis muscleIt may be associated with a nonrelaxing puborectalis muscle.
    External sphincter muscleIt may also be associated with a nonrelaxing external sphincter muscle.
    Pull-through surgery
    ProcedureA surgical procedure used to treat Hirschsprung disease.
    RemovalThe affected portion of the colon or rectum is removed.
    ReconnectionThe two healthy ends of the bowel are joined together.